GSK PLC 2013 AR2
The report highlights GlaxoSmithKline's strong performance in 2013, marked by exceptional R&D output with six major medicine approvals, including treatments for respiratory disease, melanoma, and HIV. The company returned £5.2 billion to shareholders through dividends and share buy-backs, achieving its best annual total shareholder return since formation. GSK also advanced its commitment to ethical conduct and transparency, becoming the first pharmaceutical company to sign the AllTrials campaign and enable external researchers to access detailed clinical trial data. Additionally, the company expanded access to healthcare in developing countries, notably through a strategic partnership with Save the Children and progress on its malaria vaccine candidate.
Company: GSK PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2013
Type: AR2
Pages: 256
Back to company
GSK PLC
Annual Report
The report highlights GlaxoSmithKline's strong performance in 2013, marked by exceptional R&D output with six major medicine approvals, including treatments for respiratory disease, melanoma, and HIV. The company returned £5.2 billion to shareholders through dividends and share buy-backs, achieving its best annual total shareholder return since formation. GSK also advanced its commitment to ethical conduct and transparency, becoming the first pharmaceutical company to sign the AllTrials campaign and enable external researchers to access detailed clinical trial data. Additionally, the company expanded access to healthcare in developing countries, notably through a strategic partnership with Save the Children and progress on its malaria vaccine candidate.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2013
Reporting Period
Jan 1, 2013 - Dec 31, 2013
Fiscal Year
2013
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Net Zero Target
Employees